Nomogram Based on Hemoglobin, Albumin, Lymphocyte and Platelet Score to Predict Overall Survival in Patients with T3-4N0-1 Nasopharyngeal Carcinoma

References

• Chen YP, Chan ATC, YS PB, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.006
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Tang LL, Chen YP, Mao YP, et al. Validation of the 8th Edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era. J Natl Compr Canc Netw. 2017;15(7):913–919. doi:10.6004/jnccn.2017.0121
   PubMed Web of Science ®Google Scholar
• Caudell JJ, Gillison ML, Maghami E, et al. NCCN guidelines(R) insights: head and neck cancers, version 1.2022. J Natl Compr Canc Netw. 2022;20(3):224–234. doi:10.6004/jnccn.2022.0016
   PubMed Web of Science ®Google Scholar
• Tang LL, Chen YP, Chen CB, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun. 2021;41(11):1195–1227. doi:10.1002/cac2.12218
   Web of Science ®Google Scholar
• Zhang LL, Huang MY, Fei X, et al. Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load. Ther Adv Med Oncol. 2020;12:1758835920932052. doi:10.1177/1758835920932052
   Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33:S79–84. doi:10.1007/s10875-012-9847-0
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (Siri) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167. doi:10.1002/cncr.30057
   PubMed Web of Science ®Google Scholar
• Xiong Y, Shi LL, Zhu LS, Ding Q, Ba L, Peng G. Prognostic efficacy of the combination of the pretreatment systemic immune-inflammation index and Epstein-Barr virus DNA status in locally advanced nasopharyngeal carcinoma patients. J Cancer. 2021;12(8):2275–2284. doi:10.7150/jca.52539
   PubMed Web of Science ®Google Scholar
• Mayne ST, Playdon MC, Rock CL. Diet, nutrition, and cancer: past, present and future. Nat Rev Clin Oncol. 2016;13(8):504–515. doi:10.1038/nrclinonc.2016.24
   PubMed Web of Science ®Google Scholar
• Wei YH, Wang Y, Li H, et al. A nomogram to predict survival in patients with locoregional recurrent nasopharyngeal carcinoma receiving comprehensive treatment. Front Oncol. 2022;12:892510. doi:10.3389/fonc.2022.892510
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680. doi:10.1038/s41568-020-0285-7
   PubMed Web of Science ®Google Scholar
• Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599–610. doi:10.1002/cpt.789
   PubMed Web of Science ®Google Scholar
• Jimbo H, Horimoto Y, Ishizuka Y, et al. Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer. Breast Cancer Res Treat. 2022;196(2):291–298. doi:10.1007/s10549-022-06748-4
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee J, Kim H, et al. Association between absolute lymphocyte count and overall mortality in patients with surgically resected gastric cancer. Korean J Intern Med. 2021;36(3):679–688. doi:10.3904/kjim.2019.358
   PubMed Web of Science ®Google Scholar
• Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018;13:6049–6058. doi:10.2147/IJN.S140462
   PubMed Web of Science ®Google Scholar
• Zhang GM, Zhu Y, Luo L, et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumour Biol. 2015;36(11):8537–8543. doi:10.1007/s13277-015-3613-x
   PubMedGoogle Scholar
• Peng D, Zhang CJ, Gong YQ, et al. Prognostic significance of halp (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Sci Rep. 2018;8(1):794. doi:10.1038/s41598-018-19146-y
   PubMedGoogle Scholar
• Zhao Z, Yin XN, Wang J, Chen X, Cai ZL, Zhang B. Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: a propensity matched retrospective cohort study. World J Gastroenterol. 2022;28(27):3476–3487. doi:10.3748/wjg.v28.i27.3476
   PubMed Web of Science ®Google Scholar
• Cong L, Hu L. The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2017;46:75–79. doi:10.1016/j.intimp.2017.02.027
   PubMed Web of Science ®Google Scholar
• Sun Y, Li W-F, Chen N-Y, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–1520. doi:10.1016/s1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu G-Q, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. New England J Med. 2019;381(12):1124–1135. doi:10.1056/nejmoa1905287
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80. doi:10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Xu T, Zhu G, He X, Ying H, Hu C, Phase III A. Randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. Oral Oncol. 2014;50(2):71–76. doi:10.1016/j.oraloncology.2013.11.002
   PubMed Web of Science ®Google Scholar
• Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;91(5):952–960. doi:10.1016/j.ijrobp.2015.01.002
   PubMed Web of Science ®Google Scholar
• Frikha M, Auperin A, Tao Y, et al. A randomized trial of induction docetaxel-cisplatin-5fu followed by concomitant cisplatin-Rt versus concomitant cisplatin-Rt in nasopharyngeal carcinoma (Gortec 2006-02). Ann Oncol. 2018;29(3):731–736. doi:10.1093/annonc/mdx770
   PubMed Web of Science ®Google Scholar
• Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase iii multicentre randomised controlled trial. Eur J Cancer. 2017;75:14–23. doi:10.1016/j.ejca.2016.12.039
   PubMed Web of Science ®Google Scholar
• Fan Y, Guan W, Huang R, et al. Clinical characteristics and survival outcomes of ascending, descending and mixed types of nasopharyngeal carcinoma in the non-endemic areas of China: a propensity score matching analysis. Cancer Med. 2020;9(24):9315–9325. doi:10.1002/cam4.3537
   PubMed Web of Science ®Google Scholar
• Yao JJ, Qi ZY, Liu ZG, et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Radiother Oncol. 2019;137:137–144. doi:10.1016/j.radonc.2019.04.025
   PubMed Web of Science ®Google Scholar
• Lan XW, Xiao Y, Zou XB, Zhang XM, OuYang PY, Xie FY. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3n0-1 Nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther. 2017;10:3853–3860. doi:10.2147/OTT.S133917
   PubMed Web of Science ®Google Scholar
• Gabani P, Barnes J, Lin AJ, et al. Induction chemotherapy in the treatment of nasopharyngeal carcinoma: clinical outcomes and patterns of care. Cancer Med. 2018;7(8):3592–3603. doi:10.1002/cam4.1626
   PubMed Web of Science ®Google Scholar
• Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373–2380. doi:10.1002/ijc.23173
   PubMed Web of Science ®Google Scholar
• Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14(6):433–439. doi:10.1016/j.semcancer.2004.06.006
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang N, Wang S, et al. Systemic inflammation response index is a predictor of poor survival in locally advanced nasopharyngeal carcinoma: a propensity score matching study. Front Oncol. 2020;10:575417. doi:10.3389/fonc.2020.575417
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu G, Pan Y, Li Y. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–8349. doi:10.1111/jcmm.15097
   PubMed Web of Science ®Google Scholar
• Long G, Tang W, Fu X, et al. Pre-treatment serum lactate dehydrogenase predicts distant metastasis and poor survival in nasopharyngeal carcinoma. J Cancer. 2019;10(16):3657–3664. doi:10.7150/jca.32716
   PubMed Web of Science ®Google Scholar
• Oei RW, Ye L, Huang J, et al. Prognostic value of nutritional markers in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy: a propensity score matching study. Onco Targets Ther. 2018;11:4857–4868. doi:10.2147/OTT.S165133
   PubMed Web of Science ®Google Scholar
• Peng RR, Liang ZG, Chen KH, Li L, Qu S, Zhu XD. Nomogram based on lactate dehydrogenase-to-albumin ratio (Lar) and Platelet-to-Lymphocyte Ratio (Plr) for predicting survival in nasopharyngeal carcinoma. J Inflamm Res. 2021;14:4019–4033. doi:10.2147/JIR.S322475
   PubMed Web of Science ®Google Scholar
• Miao S, Lei H, Li X, et al. Development and validation of a risk prediction model for overall survival in patients with nasopharyngeal carcinoma: a prospective cohort study in China. Cancer Cell Int. 2022;22(1):360. doi:10.1186/s12935-022-02776-8
   PubMed Web of Science ®Google Scholar
• Jiang P, Kong W, Gong C, et al. Predicting the recurrence of operable cervical cancer patients based on hemoglobin, albumin, lymphocyte, and platelet (Halp) score and classical clinicopathological parameters. J Inflamm Res. 2022;15:5265–5281. doi:10.2147/JIR.S383742
   PubMed Web of Science ®Google Scholar
• Guc ZG, Alacacioglu A, Kalender ME, et al. Halp score and gnri: simple and easily accessible indexes for predicting prognosis in advanced stage NSCLC patients. the izmir oncology group (Izog) study. Front Nutr. 2022;9:905292. doi:10.3389/fnut.2022.905292
   PubMed Web of Science ®Google Scholar
• Xu H, Zheng X, Ai J, Yang L. Hemoglobin, albumin, lymphocyte, and platelet (Halp) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients. Int Immunopharmacol. 2023;114:109496. doi:10.1016/j.intimp.2022.109496
   PubMed Web of Science ®Google Scholar
• Vlatka P, Marko L, Stefan M, Dorian L. The hemoglobin, albumin, lymphocyte, and platelet (Halp) score is a novel prognostic factor for patients with diffuse large B-cell lymphoma. J Cancer Res Ther. 2022;18(3):725–732. doi:10.4103/jcrt.jcrt_174_21
   PubMed Web of Science ®Google Scholar
• Solmaz S, Uzun O, Sevindik OG, et al. The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. Int J Lab Hematol. 2023;45(1):13–19. doi:10.1111/ijlh.13958
   PubMed Web of Science ®Google Scholar
• Wu CY, Lin YH, Lo WC, et al. Nutritional status at diagnosis is prognostic for pharyngeal cancer patients: a retrospective study. Eur Arch Otorhinolaryngol. 2022;279(7):3671–3678. doi:10.1007/s00405-021-07222-5
   PubMed Web of Science ®Google Scholar
• Chan ATC, Hui EP, Ngan RKC, et al. Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol. 2018;36(31):3091–3100. doi:10.1200/jco.2018.77.7847
   Web of Science ®Google Scholar
• Chen FP, Luo YS, Chen K, et al. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma. Eur J Cancer. 2021;151:63–71. doi:10.1016/j.ejca.2021.03.052
   PubMed Web of Science ®Google Scholar
• Li W-Z, Wu H-J, Lv S-H, et al. Assessment of survival model performance following inclusion of Epstein-Barr virus DNA status in conventional TNM staging groups in Epstein-Barr virus–related nasopharyngeal carcinoma. JAMA Network Open. 2021;4(9):e2124721. doi:10.1001/jamanetworkopen.2021.24721
   PubMed Web of Science ®Google Scholar